{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T05:01:54Z","timestamp":1777525314518,"version":"3.51.4"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000982","name":"Conquer Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Germline <jats:italic>BRCA1\/2<\/jats:italic> pathogenic variant (PV) carriers have high lifetime risk of developing breast cancer and therefore subjected to intense lifetime screening. However, solid data on the effectiveness of high-risk screening of the <jats:italic>BRCA1\/2<\/jats:italic> carrier population is limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>Retrospectively, we analyzed 346 women diagnosed with breast tumors. Patients were divided according to the timing of <jats:italic>BRCA1\/2<\/jats:italic> PVrecognition, before (BRCA-preDx awareness, N = 62) or after (BRCA-postDx awareness group, N = 284) cancer diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Median follow-up times were 131.42 and 93.77 months in the BRCA-preDx awareness and BRCA-postDx awareness groups, respectively. In the BRCA-preDx awareness group, 78.7% of the patients had invasive tumors and 21.3% were diagnosed with pure ductal carcinoma <jats:italic>in situ<\/jats:italic>. In contrast, in the BRCA-postDx awareness group over 93% of women were diagnosed with invasive cancer and only 6.4% had <jats:italic>in situ<\/jats:italic> disease. The mode of tumor detection differed significantly between the groups: 71.9% in the BRCA-postDx awareness group and 26.2% in the BRCA-preDx awareness group were diagnosed after personally palpating a lump. Tumor size and nodal involvement were significantly more favorable in the BRCA-preDx awareness group. T stage was significantly lower in the BRCA-preDx awareness group: 54.84% at T1 and 20.96% at Tis. In the BRCA-postDx awareness group, only 37.54% were at T1 and 6.49% at Tis. The N stage was also significantly lower in the BRCA-preDx awareness group: 71% had no lymph node metastases, compared with 56.1% in the BRCA-postDx awareness group. Additionally, therapeutic procedures varied between the groups: BRCA-preDx awareness group patients underwent more breast conserving surgeries. Axillary lymph node dissection was done in 38% of women in the BRCA-postDx awareness group and in only 8.7% of the BRCA-preDx awareness group patients. Interestingly, improved survival was found among patients who underwent high-risk screening (hazard ratio=0.34).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>High-risk screening might facilitate downstaging of detected breast tumor among <jats:italic>BRCA1\/2<\/jats:italic> carrier population.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.683656","type":"journal-article","created":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T02:40:32Z","timestamp":1630723232000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["\u201cHigh-Risk Breast Cancer Screening in BRCA1\/2 Carriers Leads to Early Detection and Improved Survival After a Breast Cancer Diagnosis\u201d"],"prefix":"10.3389","volume":"11","author":[{"given":"Shay","family":"Shraga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Grinshpun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviad","family":"Zick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luna","family":"Kadouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yogev","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofra","family":"Maimon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Adler-Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Zeltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Avital","family":"Granit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bella","family":"Maly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Einat","family":"Carmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vardiella","family":"Meiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Sella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Hamburger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamar","family":"Peretz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-018-5057-7","article-title":"Trends in Use of Bilateral Prophylactic Mastectomy vs High-Risk Surveillance in Unaffected Carriers of Inherited Breast Cancer Syndromes in the Inherited Cancer Registry (ICARE)","volume":"174","author":"Henry","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.5603\/NMR.2017.0002","article-title":"Breast Cancer: Early Diagnosis and Effective Treatment by Drug Delivery Tracing","volume":"20","author":"Shamsi","year":"2017","journal-title":"Nucl Med Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25971","article-title":"Effectiveness of Alternating Mammography and Magnetic Resonance Imaging for Screening Women With Deleterious BRCA Mutations at High Risk of Breast Cancer","volume":"117","author":"Le-Petross","year":"2011","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-019-05152-9","article-title":"High-Risk Breast Cancer Surveillance With MRI: 10-Year Experience From the German Consortium for Hereditary Breast and Ovarian Cancer","volume":"175","author":"Bick","year":"2019","journal-title":"Breast Cancer Res Treat"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1210\/er.2009-0041","article-title":"Broadening Criteria for BRCA1\/2 Evaluation","volume":"31","author":"Domchek","year":"2010","journal-title":"Endocr Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.8430","article-title":"Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA- Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force","volume":"322","author":"Nelson","year":"2019","journal-title":"JAMA - J Am Med Assoc"},{"key":"B7","doi-asserted-by":"publisher","first-page":"77","DOI":"10.6004\/jnccn.2021.0001","article-title":"Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic","volume":"19","author":"Daly","year":"2021","journal-title":"JNCCN"},{"key":"B8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s13053-016-0048-3","article-title":"Intensive Breast Screening in BRCA2 Mutation Carriers Is Associated With Reduced Breast Cancer Specific and All Cause Mortality","volume":"14","author":"Evans","year":"2016","journal-title":"Hered Cancer Clin Pract"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29534","article-title":"Survival Benefit in Women With BRCA1 Mutation or Familial Risk in the MRI Screening Study (MRISC)","volume":"137","author":"Saadatmand","year":"2015","journal-title":"Int J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1159\/000375390","article-title":"Intensified Surveillance for Early Detection of Breast Cancer in High-Risk Patients","volume":"10","author":"Bick","year":"2015","journal-title":"Breast Care"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0b013e3181fe714e","article-title":"Breast Cancer Screening in Women at Average Risk and High Risk","volume":"116","author":"Griffin","year":"2010","journal-title":"Obstet Gynecol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2016.07.011","article-title":"Determination of Recall Rates for Assessment in High-Risk Women Undergoing Annual Surveillance Breast MRI","volume":"71","author":"Healy","year":"2016","journal-title":"Clin Radiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1093\/aje\/kwn120","article-title":"Correcting for Lead Time and Length Bias in Estimating the Effect of Screen Detection on Cancer Survival","volume":"168","author":"Duffy","year":"2008","journal-title":"Am J Epidemiol"},{"key":"B14","article-title":"Breast Cancer Screening and Diagnosis The University of Texas","year":"2020"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.breastdis.2013.01.034","article-title":"Annual Screening Strategies in BRCA1 and BRCA2 Gene Mutation Carriers: A Comparative Effectiveness Analysis","volume":"24","author":"Lee","year":"2013","journal-title":"Breast Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.27.0835","article-title":"Prospective Study of Breast Cancer Incidence in Women With a BRCA1 or BRCA2 Mutation Under Surveillance With and Without Magnetic Resonance Imaging","volume":"29","author":"Warner","year":"2011","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66481-1","article-title":"Screening With Magnetic Resonance Imaging and Mammography of a UK Population at High Familial Risk of Breast Cancer: A Prospective Multicentre Cohort Study (MARIBS)","volume":"365","author":"Leach","year":"2005","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0900212","article-title":"New England Journal Medicine","volume":"361","author":"Fong","year":"2009","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.8.931-a","article-title":"Surveillance of BRCA1 and BRCA2 Carriers","volume":"293","author":"Helvie","year":"2005","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173","article-title":"Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10666","article-title":"A BRCA1\/2 Mutation, High Breast Density and Prominent Pushing Margins of a Tumor Independently Contribute to a Frequent False-Negative Mammography","volume":"102","author":"Tilanus-Linthorst","year":"2002","journal-title":"Int J Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1136\/jech.52.4.267","article-title":"Effect of Mammographic Breast Density on Breast Cancer Screening Performance: A Study in Nijmegen, the Netherlands","volume":"52","author":"Van Gils","year":"1998","journal-title":"J Epidemiol Community Health"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/93.14.1095","article-title":"Magnetic Resonance Imaging and Mammography in Women With a Hereditary Risk of Breast Cancer","volume":"93","author":"Stoutjesdijk","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh269","article-title":"Factors Contributing to Mammography Failure in Women Aged 40 \u2013 49 Years","volume":"96","author":"Buist","year":"2004","journal-title":"JNCI: J Nat Cancer Institute"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.18.1533","article-title":"Re: Biologic Characteristics of Interval and Screen-Detected Breast Cancers [2]","volume":"92","author":"Eisinger","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"B26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3322\/canjclin.57.2.75","article-title":"American Cancer Society Guidelines for Breast Screening With MRI as an Adjunct to Mammography","volume":"57","author":"Saslow","year":"2007","journal-title":"ACS J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27864.Cost-Effectiveness","article-title":"Cost-Effectiveness of Alternating MRI and Digital Mammography Screening in BRCA1 and BRCA2 Gene Mutation Carriers","volume":"119","author":"Chubiz","year":"2014","journal-title":"Cancer"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.8331","article-title":"Effectiveness of Screening With Annual Magnetic Resonance Imaging and Mammography: Results of the Initial Screen From the Ontario High Risk Breast Screening Program","volume":"32","author":"Chiarelli","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2059","article-title":"Presymptomatic Awareness of Germline Pathogenic BRCA Variants and Associated Outcomes Inwomen With Breast Cancer","volume":"382","author":"Hadar","year":"2020","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.683656\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T02:40:35Z","timestamp":1630723235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.683656\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":29,"alternative-id":["10.3389\/fonc.2021.683656"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.683656","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"article-number":"683656"}}